PK/ADME Studies CROs

Formerly Covance, Labcorp Drug Development provides comprehensive drug development services from early discovery through post-approval. One of the world's largest CROs with extensive nonclinical and clinical capabilities.

Leading global pharmaceutical and medical device open-access capability and technology platform. WuXi AppTec provides services spanning from discovery through manufacturing across small molecules, biologics, and cell/gene therapies.

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Contract research organization providing drug discovery and development services including preclinical safety assessment, bioanalytical services, and research animal models.

Preclinical CRO specializing in in vitro pharmacology, receptor binding, enzyme inhibition assays, and ADME screening for drug discovery programs.

Specialized early clinical research CRO providing Phase I clinical pharmacology, bioanalytical, and ADME services from dedicated clinical units.

San Diego-based preclinical CRO providing in vitro ADME screening, permeability assays, and metabolic stability studies for drug discovery programmes.

CRO providing integrated drug discovery and development services including ADME/PK, bioanalytical, CMC, and clinical services with operations in the US and China.

Japanese preclinical CRO providing GLP safety assessment, pharmacokinetics, and toxicology studies with specialized NHP and inhalation toxicology capabilities from facilities in Japan and the US.

Labcorp Drug Development's Japanese operations providing preclinical safety assessment, bioanalytical services, and clinical trial support for regulatory submissions to PMDA and other Asian regulatory agencies.

Chinese integrated drug discovery and development CRO providing medicinal chemistry, ADME/PK, pharmacology, toxicology, and CMC services from Shanghai operations.

Integrated pharmaceutical R&D service platform offering drug discovery, preclinical, clinical, and commercial manufacturing services to biotech and pharma companies globally.

Drug discovery and development company offering a range of discovery and preclinical services including target validation, hit identification, lead optimization, and ADME/PK.

Mid-size CRO offering early-phase clinical studies, preclinical safety assessment, and bioanalytical services. Known for integrated PK/PD programs from preclinical through Phase I.

Integrated drug discovery and development services company now part of Evotec. Provides ADME/DMPK, safety assessment, and pharmaceutical development services.

Sydney-based Phase 1 clinical pharmacology unit specializing in first-in-human studies, bioequivalence, and healthy volunteer trials. Part of the Novotech group.

Leading Australian Phase 1 clinical trials unit operating in Melbourne, Brisbane, and Minneapolis. Specializes in first-in-human, oncology Phase 1, and healthy volunteer studies with rapid enrollment timelines.

Adelaide-based Phase 1 clinical pharmacology unit conducting first-in-human, bioequivalence, and biosimilar studies. Operates a 150-bed facility at the Royal Adelaide Hospital campus.

Brisbane-based Phase 1 clinical trial unit specializing in first-in-human, pharmacokinetic, and vaccine studies. Operates a dedicated clinical pharmacology unit at QIMR Berghofer campus.

Transatlantic Phase 1 CRO with clinical pharmacology units in Rennes (France) and Newark (NJ, USA). Specializes in first-in-human, CNS, cardiac safety, and abuse liability studies.

Specialty CRO focused on cardiometabolic clinical trials. Operates Phase 1–2 studies for obesity, diabetes, NASH/MASH, and cardiovascular endpoints with proprietary biomarker platforms.

Labcorp's early development and Phase 1 clinical unit operating dedicated clinical pharmacology facilities. Provides first-in-human, bioavailability/bioequivalence, and thorough QT studies.

Translational pharmaceutics CRO integrating drug substance, drug product, and clinical testing in a single facility. Specializes in formulation development with integrated Phase 1 studies.

London-based Phase 1 clinical research unit specializing in early phase clinical trials, pharmacokinetics, and healthy volunteer studies. Located at Guy's Hospital campus.

London-based early phase CRO conducting Phase 1 healthy volunteer and patient studies. Operates a dedicated clinical pharmacology unit at the Cumberland Business Park with 100+ bed capacity.

US-based early phase CRO specializing in cardiac safety (thorough QT/QTc) studies, abuse deterrent formulation, and human abuse liability studies. Operates a 120-bed clinical facility.

Netherlands-based CRO providing Phase I clinical pharmacology, bioequivalence, and early-phase clinical trial services as the European arm of India's Veeda Group.

Indian bioanalytical and clinical research laboratory providing BA/BE studies, pharmacokinetic analysis, and analytical method development for generic and innovative drug programs.

Ahmedabad-based CRO with a 350-bed Phase I clinical pharmacology unit, specializing in early-phase clinical trials, BA/BE studies, and bioanalytical services for global pharma clients.

US arm of Australian CRO Nucleus Network, operating early phase clinical trials from their Minneapolis facility. Provides Phase 1 studies with access to diverse patient populations.

Fully integrated German CRO/CDMO offering drug discovery, non-clinical studies, pharmaceutical analysis, GMP manufacturing, and early-phase clinical trials from facilities in Germany and France.

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

Swiss independent Phase I and early-phase clinical CRO in Basel with a dedicated 24-bed clinical pharmacology unit, specializing in first-in-human studies for oncology, cardiovascular, and CNS compounds.

Denmark-based GLP preclinical CRO offering safety pharmacology, general toxicology, reproductive toxicology, and ADME studies, known for rodent and non-rodent capabilities including minipig models.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Large preclinical CRO in Michigan acquired by Charles River Laboratories, providing GLP toxicology, safety pharmacology, and ADME studies in purpose-built facilities spanning over 800,000 sq ft.

US subsidiary of Shin Nippon Biomedical Laboratories specializing in GLP preclinical safety assessment including general toxicology, reproductive toxicology, and inhalation studies with NHP and rodent capabilities.

Independent nonprofit applied science and technology organization providing preclinical research, inhalation toxicology, bioanalytical services, and pharmaceutical development support.

Bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand binding assay services for pharmacokinetic, bioequivalence, and immunogenicity sample analysis to support clinical trials.

Virginia-based safety pharmacology CRO providing cardiovascular telemetry, respiratory, and CNS safety studies in rodent and non-rodent species.

Preclinical CRO in Pennsylvania providing GLP and non-GLP toxicology, safety pharmacology, and pathology services with a focus on small and large molecule therapeutics.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

Full-service clinical CRO providing Phase I-IV development support with emphasis on bioanalytical services, clinical pharmacology, and PK/PD modeling from their Salt Lake City operations.

ICON's dedicated bioanalytical division providing GLP-compliant small and large molecule bioanalysis, immunogenicity testing, and biomarker analysis from state-of-the-art laboratories.

Preclinical ADME and pharmacokinetics CRO in Pennsylvania providing in vitro and in vivo absorption, distribution, metabolism, and excretion studies as part of Pharmaron's global network.

Phase I clinical research unit in New Jersey providing first-in-human, food effect, bioequivalence, and early-phase pharmacokinetic studies for pharmaceutical sponsors.

Clinical pharmacology and bioanalytical CRO providing Phase I studies, bioequivalence, and PK/PD studies from a purpose-built 150-bed clinical pharmacology unit in Dilworth, Minnesota.

Drug discovery services company providing in vitro pharmacology screening, ADME profiling, and custom assay development for pharmaceutical and biotech companies.

Clinical pharmacology consulting firm specializing in PK/PD modeling, dose optimization, biosimilar development strategy, and regulatory science for pharmaceutical and biotech companies.

ICON's dedicated early development division operating clinical pharmacology units in the US and Europe, conducting first-in-human, PK/PD, food effect, and drug interaction studies.

Global CRO/CDMO providing integrated drug discovery and development services including medicinal chemistry, ADME/PK, pharmacology, and process chemistry from US and China operations.

Translational pharmaceutics CRO/CDMO uniquely combining formulation development and clinical pharmacology under one roof, accelerating drug development timelines by running formulation and clinical testing simultaneously.

Chinese preclinical CRO providing GLP-compliant safety evaluation, pharmacokinetics, efficacy studies, and drug metabolism studies with comprehensive NHP and rodent capabilities.

Chinese CRO/CDMO providing integrated drug discovery services including structure-based drug design, medicinal chemistry, ADME/PK studies, and biologics development from Shanghai operations.

Indian integrated research, development, and manufacturing services company serving pharma, biotech, and nutrition companies with discovery chemistry, biology, and manufacturing capabilities.

Indian clinical CRO providing Phase I-IV clinical trials, bioanalytical services, and clinical pharmacology studies with dedicated Phase I units and bioanalytical laboratories.

Indian research services company providing medicinal chemistry, computational chemistry, biology, DMPK, and clinical development services for global pharma and biotech companies.

Integrated drug discovery and development services company providing medicinal chemistry, ADME/DMPK, pharmacology, and clinical research from India, US, and China operations.

Novotech's dedicated Phase I research unit in Sydney providing first-in-human, SAD/MAD, food effect, and bioavailability studies with a 30-bed clinical pharmacology facility.

Indian CRO providing Phase I clinical pharmacology, bioanalytical services, and bioequivalence studies from a 230-bed clinical pharmacology unit in Ahmedabad with USFDA and EMA track record.

GLP-compliant preclinical CRO specializing in toxicology, pathology, and ADME studies for pharmaceutical, biotech, and agrochemical clients with full necropsy and histopathology capabilities.

Specialist bioanalytical, biomarker, and analytical sciences CRO with 500+ experts providing FDA/EMA-inspection-ready regulated bioanalysis across the US, UK, and Australia.

Canadian full-service CRO providing clinical research services from Phase I through Phase IV with particular expertise in bioequivalence studies and pharmacokinetic trials.

Labcorp Drug Development's Chinese laboratory providing preclinical safety assessment, bioanalytical services, and clinical trial support for NMPA regulatory submissions.

Australian bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand binding assay services for pharmacokinetic, bioequivalence, and immunogenicity studies supporting global regulatory submissions.

Chinese CRO and CDMO providing drug discovery chemistry, DMPK, analytical services, and clinical trial manufacturing from Shanghai and Chengdu operations.

South Korean pharmaceutical research institute providing preclinical safety assessment, ADME/PK studies, and efficacy testing from GLP-certified facilities in Seoul.

Chinese operations of Frontage Laboratories providing bioanalytical services, ADME/PK studies, and analytical chemistry from GLP-compliant laboratories in Shanghai and Suzhou.

Japanese preclinical ADME services company providing in vitro metabolism, transporter, and drug interaction studies using human and animal tissue preparations for drug development.

Italian CRO providing Phase I clinical pharmacology studies including bioequivalence, food-effect, and drug interaction trials from its dedicated Phase I unit in Milan.

Nordic preclinical CRO providing in vivo pharmacology, efficacy, and safety studies with expertise in metabolic disease, inflammation, and fibrosis models using rodent species.

Full-service CRO purpose-built for small and mid-size biotech, combining legacy of CATO Research, SMS Oncology, Pharm-Olam, and Nuventra into an integrated clinical development partner.

Leading bioanalytical CRO with 45+ years of experience supporting 315+ approved drugs, offering LC-MS, ELISA, flow cytometry, and immunogenicity assays.

GLP-compliant bioanalytical CRO with 25+ years of LC-MS/MS and GC-MS/MS expertise supporting preclinical-to-clinical drug development from purpose-built facilities.

Leading large molecule bioanalytical CRO specializing in ligand-binding assays, immunogenicity testing, flow cytometry, and biomarker analysis for biologics drug development.

Not-for-profit preclinical CRO with ABSL-3 capabilities and expertise in inhalation toxicology, pulmonary delivery, and infectious disease models from 100+ acre campus.

Hyderabad-headquartered integrated CRDMO providing CRO and CDMO solutions for small and large molecules to 450+ global pharma and biotech clients with 3,000+ professionals.

Shanghai-headquartered CRO/CDMO offering integrated drug discovery chemistry, biology, and biologics development services including ADC and recombinant protein production.

Italian preclinical CRO providing GLP safety pharmacology, general and genetic toxicology, DMPK, and bioanalytical services from Nerviano (Milan) facilities.

Germany-based mid-size CRO providing early-phase clinical trials (Phase I/IIa), bioanalysis, DMPK, and translational medicine services from facilities in Neu-Ulm and Berlin.

Swiss clinical pharmacology unit specialising in first-in-human Phase I trials, PK/PD studies, and early-phase bioequivalence studies for small molecules and biologics.

Specialist bioanalytical CRO combining LC-MS/MS, mass spectrometry imaging, and spatial biology platforms to support regulated discovery and clinical sample analysis.

World's largest nonprofit R&D organization offering GLP-compliant preclinical safety, toxicology, inhalation studies, and bioanalytical services including BSL-3 biocontainment capabilities.

Independent not-for-profit preclinical CRO offering full IND-enabling GLP toxicology programs, inhalation toxicology, and immunogenicity testing from the Illinois Institute of Technology campus.

Specialty preclinical CRO offering bioanalytical chemistry, in vitro ADME screening, physicochemical profiling, and metabolite identification for drug discovery programs.

Specialist topical and transdermal formulation development CRO and CDMO offering dermal PK, in vitro permeation, bioequivalence, and formulation development services.

Clinical trial arm of Frontage Laboratories providing Phase I-III services with integrated bioanalytical capabilities, bridging bioanalytical strength with full clinical execution.

European CRO providing preclinical contract research services including in vivo pharmacology, toxicology, and bioanalytical testing from GLP-certified European facilities.

European ADME and DMPK specialist CRO providing in vitro ADME screening, drug-drug interaction studies, and physicochemical profiling from Macclesfield and Watertown facilities.

Croatian integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, and preclinical development services, now part of Polish CRO Selvita Group.

Labcorp Drug Development's UK preclinical facility providing GLP toxicology, safety pharmacology, and reproductive toxicology studies from Harrogate, North Yorkshire.

Japan's pioneering CRO founded in 1957 offering non-clinical safety evaluation including NHP studies, clinical Phase I-IV development, and a proprietary nasal drug delivery platform.

Polish integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, computational chemistry, and preclinical services with 1,000+ scientists across Europe.

Founder-led bioanalytical CRO providing GLP-compliant LC-MS, ELISA, and qPCR services for PK, immunogenicity, and biomarker assays for pharma and biotech.

Kobe-based Japanese CRO and research institute specializing in preclinical safety assessment, pharmacology and drug metabolism studies with GLP-accredited facilities.

Hyderabad-based publicly listed contract research and testing organisation offering integrated preclinical, clinical, and cGMP laboratory services for pharmaceutical companies worldwide.

India-based integrated CDMO and CRO providing API R&D, formulation development, bioanalytical services, and Phase I-IV clinical research from facilities in Hyderabad.

California-based bioanalytical CRO providing LC-MS/MS method development, validation, and sample analysis for PK/PD studies supporting IND and NDA submissions.

Canadian bioanalytical CRO providing GLP-compliant LC-MS/MS bioanalytical services, PK analysis, and method development for pharmaceutical and biotech sponsors.

Specialised bioanalytical laboratory in New York providing large-molecule bioanalysis, immunogenicity testing, and ligand-binding assay development for biologics programmes.

LabCorp Drug Development preclinical and toxicology centre in Madison, Wisconsin, providing GLP-compliant general and genetic toxicology, safety pharmacology, and reproductive toxicology studies.

Kansas City-based in vitro ADME and drug metabolism CRO providing hepatocyte-based assays, enzyme induction/inhibition studies, and metabolite identification services.

Exton, Pennsylvania-based preclinical CRO providing in vivo PK/PD studies, ADME services, and GLP bioanalytical testing for small-molecule and biologic drug candidates.

Verona, Italy-based integrated drug discovery and development centre providing medicinal chemistry, DMPK, safety assessment, and pharmaceutical development under the Evotec umbrella.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Indian CRO affiliated with Dabur offering preclinical drug discovery, IND-enabling studies, and non-clinical research services from facilities near Delhi.

One of China's earliest chemistry-focused CROs offering integrated drug discovery, DMPK, and pharmaceutical development services globally.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Kentucky-based preclinical CRO specialising in oncology efficacy studies using proprietary humanised rodent models and patient-derived xenografts for immuno-oncology drug development.

Netherlands-based bioanalytical centre of excellence providing large-molecule bioanalysis, immunogenicity, and cell-based assay services for biologics and biosimilar programmes.

Texas-based Phase I clinical research unit specialising in early-phase, first-in-human, and healthy volunteer studies with integrated bioanalytical capabilities.

Oklahoma-based early-phase clinical research site specialising in Phase I healthy volunteer studies, PK/PD trials, and bioequivalence studies.

New York-based Phase I CRO operating an 80-bed clinical pharmacology unit for first-in-human, CNS, cardiac safety, and abuse liability studies.

Pennsylvania-based bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand-binding assay services for PK, immunogenicity, and biomarker analysis.

Shanghai-based preclinical CRO providing in vivo pharmacology, toxicology, DMPK, and bioanalytical services with specialized PDX platforms for oncology drug development.

Singapore-based specialty CRO providing preclinical pharmacology, toxicology, and early clinical development services with particular expertise in biologics and biosimilar characterization.

Santiago-based Phase I clinical pharmacology unit providing first-in-human, BA/BE, and pharmacokinetic studies for Latin American and international sponsors under ICH-GCP standards.

Celerion's clinical pharmacology facility in Lincoln, Nebraska, providing early-phase clinical trials, BA/BE studies, and cardiac safety testing with a 200+ bed Phase I unit.

Inotiv's preclinical facility in Boulder, Colorado, providing GLP toxicology, safety pharmacology, and DMPK studies with capabilities in cardiovascular, respiratory, and CNS safety assessment.

Zagreb-based drug discovery CRO (Selvita Group) providing integrated medicinal chemistry, ADME/PK, and in vitro biology services for hit-to-lead and lead optimization programs.

Evotec's integrated drug development campus in Verona, Italy, providing DMPK, toxicology, formulation, and clinical manufacturing services as a one-stop discovery-through-Phase II partner.

Nuvisan's Integrated Contract Bioscience facility in Neu-Ulm, Germany, providing preclinical ADME, bioanalysis, and Phase I clinical trials with a 120-bed clinical pharmacology unit.

Welsh-based early-phase CRO providing Phase I clinical pharmacology, FTIH studies, and paediatric clinical trials with a 72-bed residential unit and dedicated bioanalytical laboratory.

Adelaide-based Australian Phase I clinical pharmacology unit within the Royal Adelaide Hospital, conducting first-in-human, BA/BE, and cardiac safety studies with a 48-bed facility.

Hyderabad-based Indian CRO providing contract research in discovery chemistry, biology, DMPK, and clinical development with integrated data analytics platform GOSTAR.

Shanghai campus of BioDuro-Sundia providing integrated discovery and development services including medicinal chemistry, DMPK, biology, and preclinical development for global biotech.

Fully integrated dermatology-dedicated CRO providing nonclinical through Phase III development services exclusively for skin disease products since 1997.

Preclinical neuroscience CRO spun out of GlaxoSmithKline in 2010, specializing in in vivo CNS pharmacology models for psychedelic compound and neurodegeneration research.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

Fully independent European preclinical CRO in Madrid delivering GLP-certified toxicology and safety studies aligned with EMA and FDA regulatory requirements.

GLP/GMP-certified European bioanalytical and CMC CRO near Barcelona with four laboratories and 240 experts serving the full pharmaceutical product lifecycle since 2001.

Full-service CRO integrating translational sciences, clinical pharmacology, bioanalysis, and regulatory strategy from preclinical through Phase IV development.

Canadian Phase I and bioequivalence CRO with a 150-bed clinical facility in Toronto and over 2,500 completed BA/BE and early-phase studies for global pharma clients.

Dr. Reddy's wholly-owned integrated CRO and CDMO for small molecules and biologics, combining 650+ Indian scientists with GMP manufacturing in the UK, Mexico, and India.

Global preclinical and drug discovery CRO offering the world's largest catalog of human fresh tissue assays for efficacy, ADME, and safety testing in GLP-accredited labs across the US, UK, and Japan.

GLP-compliant preclinical CRO in Austin, Texas, offering 100+ validated xenograft efficacy models, IND-enabling toxicology, and RNAi therapeutic development services.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.

New Jersey-based bioanalytical and ADME/DMPK CRO founded in 1987, providing clinical and nonclinical metabolism and pharmacokinetics services to pharma, biotech, and agrochemical industries.

Specialist preclinical ophthalmology CRO with AAALAC-accredited labs in Oklahoma City and Ann Arbor, providing pharmacology, PK/tox, bioanalysis, and formulation services for ocular drug development.

Specialty preclinical CRO focused on non-GLP ophthalmic and oncology efficacy studies, providing in vivo animal model services for ocular disease and solid tumor drug development.

Specialty ADME/PK CRO providing in vitro and in vivo drug metabolism and pharmacokinetic studies. Known for comprehensive ADME characterization using human and animal tissues.

Preclinical ADME and pharmacokinetic service provider now part of Pharmaron. Specializes in in vitro and in vivo DMPK, drug transporter studies, and metabolite identification.